Addex Therapeutics Ltd
ADXN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $30 | $36 | $0 | $2 |
| % Growth | -18.3% | – | -100% | – |
| Cost of Goods Sold | $0 | $234 | $0 | $0 |
| Gross Profit | $30 | -$198 | $0 | $2 |
| % Margin | 100% | -544.5% | – | 100% |
| R&D Expenses | $85 | $68 | $33 | -$6 |
| G&A Expenses | $460 | $412 | $448 | $261 |
| SG&A Expenses | $460 | $412 | $448 | $261 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $181 | $54 | $126 | $193 |
| Operating Expenses | $726 | $535 | $606 | $447 |
| Operating Income | -$696 | -$733 | -$606 | -$446 |
| % Margin | -2,342.1% | -2,014.8% | – | -29,550.8% |
| Other Income/Exp. Net | -$881 | -$1,226 | -$867 | -$744 |
| Pre-Tax Income | -$1,577 | -$1,959 | -$1,473 | -$1,190 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,577 | -$1,841 | -$1,473 | -$1,206 |
| % Margin | -5,306.3% | -5,061.6% | – | -79,956% |
| EPS | -1.2 | -2.56 | -1.8 | -1.45 |
| % Growth | 53.1% | -42.2% | -24.1% | – |
| EPS Diluted | -1.2 | -2.4 | -1.8 | -1.48 |
| Weighted Avg Shares Out | 939 | 721 | 820 | 815 |
| Weighted Avg Shares Out Dil | 939 | 767 | 820 | 815 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | -$0 |
| Interest Expense | $0 | $1 | $1 | $1 |
| Depreciation & Amortization | $2 | $2 | $2 | $24 |
| EBITDA | -$1,575 | -$1,956 | -$1,470 | -$1,165 |
| % Margin | -5,297.5% | -5,377.2% | – | -77,224.3% |